Bone markers in osteoporosis.
Current biological markers of bone turnover have proven useful in improving fracture risk assessment and monitoring treatment efficacy in postmenopausal osteoporosis. Recent developments in the field of bone markers include 1) identification of new biochemical markers providing additional information on the complex pathways leading to bone fragility; 2) application of novel technologies such as proteomics for the discovery of novel markers; 3) automation and multiplexing for improving analytical performance and convenience; and 4) refinement of the clinical interpretation of markers. Currently, however, for the management of individual patients, their most established application is to monitor treatment efficacy and possibly to improve fracture risk assessment. The role of bone markers for improving adherence to therapy will need to be investigated in further studies. This brief review discusses these novel technological developments and the recent clinical data on the use of established and new markers in postmenopausal osteoporosis.
Garnero
Patrick
P
Synarc, 16 rue Montbrillant, 69003 Lyon, France. patrick.garnero@synarc.com
D015415:Biomarkers / Q000097:blood*; D015992:Body Mass Index; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000097:blood* / Q000175:diagnosis*; D018570:Risk Assessment
D015415:Biomarkers